Trehalose-6-Phosphate is an investigational drug.
There have been 17 clinical trials for Trehalose-6-Phosphate.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Alzheimer Disease, Macular Edema, and Parkinson Disease. The leading clinical trial sponsors are Seelos Therapeutics, Inc., Mashhad University of Medical Sciences, and Bioblast Pharma Ltd.
There are ten US patents protecting this investigational drug and fifty-three international patents.